Feb 02, 2026 · Motley Fool Money · 5 min read

Biotech FDA Chaos and GLP-1 Earnings Outlook

Analysis of FDA regulatory turbulence impacting gene therapy approvals and the competitive landscape for Eli Lilly and Novo Nordisk. Insights on biotech valuation trends and the strategic shift toward M&A in the GLP-1 market.

Business Investing

The takeaways

FDA Regulatory Chaos Increases Biotech Risk. Investors must account for heightened regulatory unpredictability, as FDA internal conflicts and political interference create inconsistent approval standards for gene and cell therapies.
GLP-1 Dominance Drives Big Pharma Valuations. Eli Lilly is now effectively a biotech company driven by GLP-1 weight-loss drugs, with consensus expecting continued earnings beats despite formulary challenges from competitors.
Novo Nordisk Prioritizes M&A Over Dividends. Novo Nordisk's new CEO is signaling a shift toward aggressive acquisitions, making a near-term dividend initiation unlikely as the company conserves cash for strategic growth.
Twist Bioscience Demonstrates Resilient Revenue Growth. Twist Bioscience has maintained consistent revenue growth and reduced cash burn over five years, positioning it favorably despite the broader biotech winter and FDA uncertainties.
Gene Therapy Approvals Face Unpredictable Delays. Recent clinical holds on unrelated gene therapies indicate FDA is raising the bar for rare disease approvals, requiring investors to extend timelines for biotech development milestones.
Biotech Outperforms Tech in 2025. The XBI index outperformed NVIDIA in 2025, signaling a sector recovery that continues into 2026, though specific subsectors like gene therapy remain high-risk.

The Biotech Sector: Recovery Amid Regulatory Turbulence

The biotechnology sector is experiencing a significant resurgence in 2026, following a strong performance in 2025 where the XBI index outperformed major tech giants like NVIDIA. However, this optimism is tempered by emerging regulatory risks at the FDA, which is creating uncertainty for investors in the gene and cell therapy spaces.

FDA Regulatory Uncertainty

A primary concern for biotech investors is the "chaos" currently unfolding at the FDA. Former senior executive Richard Pazdur warned that the firewall between political appointees and drug reviewers has been breached, leading to inconsistent regulatory approaches. While FDA Commissioner Martin Khari has expressed intent to speed up approvals through mechanisms like "plausible mechanism" pathways, on-the-ground reality contradicts this. Recent examples, such as the unexpected clinical hold on Regenix Bio's Hunter syndrome drug due to unrelated safety concerns in a different gene therapy, suggest the agency is actually raising the bar for rare disease approvals. This unpredictability forces investors to build in longer timelines and higher risk premiums for companies dependent on fast-track FDA approvals.

GLP-1 Market Dynamics

The weight-loss drug market remains the dominant driver for large-cap biotech and pharma companies. Eli Lilly is positioned to beat earnings estimates, driven by the success of its GLP-1 drugs, despite some formulary challenges from CVS. In contrast, Novo Nordisk faces a more complex landscape. With a new CEO signaling a shift toward aggressive M&A, the company is likely to conserve cash rather than initiate a dividend. This strategic pivot suggests Novo Nordisk is prioritizing long-term market share expansion over short-term shareholder returns, a move that may stabilize investor confidence in the medium term.

Emerging Growth Opportunities

Twist Bioscience offers a contrasting narrative of resilience. By providing DNA synthesis services to researchers, the company has maintained consistent revenue growth and reduced cash burn over the past five years, even during the biotech winter. Its valuation has normalized from extreme highs to a more reasonable multiple, making it an attractive play for investors seeking exposure to biotech infrastructure without the direct regulatory risks of drug development.

Conclusion

While the biotech sector shows strong momentum, investors must navigate a complex landscape of regulatory unpredictability and shifting corporate strategies. Diversification across subsectors, from established GLP-1 leaders to infrastructure plays like Twist Bioscience, is key to managing risk in this evolving market.

Key insights

FDA regulatory processes are becoming increasingly unpredictable due to political interference and internal turnover, leading to inconsistent approval standards for gene therapies.

Regulatory Risk →

Impact: Investors must adjust valuation models for biotech companies to account for longer approval timelines and higher probability of clinical holds.
Eli Lilly's business model has shifted significantly, with GLP-1 weight-loss drugs now acting as the primary driver of earnings and valuation, effectively reclassifying it as a biotech-focused entity.

Market Dynamics →

Impact: The success of GLP-1 drugs is reshaping the competitive landscape, with formulary decisions by major pharmacies becoming a critical risk factor for revenue stability.
Novo Nordisk is undergoing a strategic transformation under new leadership, prioritizing aggressive M&A over dividend initiation to secure long-term market position.

Corporate Strategy →

Impact: This shift signals a focus on growth and market share expansion, which may appeal to growth-oriented investors but disappoint those seeking immediate income.
Twist Bioscience has demonstrated operational resilience by maintaining revenue growth and reducing cash burn over five years, despite the broader biotech downturn.

Operational Efficiency →

Impact: The company's stable growth trajectory and normalized valuation make it a lower-risk entry point into the biotech sector compared to drug developers.
The biotech sector's outperformance of tech stocks in 2025 indicates a broader market rotation, but specific subsectors like gene therapy remain high-risk due to regulatory and clinical uncertainties.

Market Trends →

Impact: Sector-wide optimism may mask underlying risks in specific therapeutic areas, requiring investors to conduct granular analysis rather than relying on broad index performance.

Action items

Reassess risk premiums for biotech companies involved in gene and cell therapies, factoring in potential FDA approval delays and clinical holds.

Impact: Adjusting valuation models to reflect regulatory uncertainty can prevent overvaluation of companies dependent on fast-track approvals.
Monitor formulary decisions by major pharmacy chains like CVS, as these directly impact the revenue stability of GLP-1 drug manufacturers like Eli Lilly.

Impact: Early identification of formulary shifts allows investors to anticipate revenue headwinds and adjust portfolio allocations accordingly.
Evaluate Novo Nordisk's M&A strategy as a key driver of long-term value, rather than focusing on short-term dividend expectations.

Impact: Aligning investment thesis with the company's strategic pivot to acquisitions can capture value from successful integrations and market expansion.
Consider allocating to biotech infrastructure companies like Twist Bioscience for exposure to sector growth with lower regulatory risk.

Impact: Diversifying into infrastructure plays provides a hedge against the specific clinical and regulatory risks associated with drug development.
Conduct granular analysis of biotech subsectors, distinguishing between high-growth areas like GLP-1 and high-risk areas like gene therapy.

Impact: Avoiding broad sector bets and focusing on specific therapeutic areas can improve risk-adjusted returns in a volatile market.

Quotes

“I was worried that the firewall of between political appointees and drug reviewers has been breached”

“The pharma industry is continuing to underestimate the damage that's already been done”

“They've consistently growing revenue through this period of the last from a tw from 2020 through to last year, adding about 60 million in revenue per year”